Clinical trial
A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
NCT03969004 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
- Lead sponsor
- Regeneron Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- June 4, 2019
- Completion date
- January 7, 2028
- Enrollment
- 415 (actual)
- Sites
- 166
Conditions
As the registry lists them; a condition with its own page is linked.